A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2001
11/01/2001	WO2001081928A1 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
11/01/2001	WO2001081918A1 Transcriptionally regulated g protein-coupled receptor g2a
11/01/2001	WO2001081599A2 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors
11/01/2001	WO2001081590A2 Protein phosphatases
11/01/2001	WO2001081585A2 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	WO2001081577A2 Dna encoding the prost 03 polypeptide
11/01/2001	WO2001081574A2 Regulation of nf-at interacting protein nip 45 variant
11/01/2001	WO2001081573A1 Edg8 receptor, its preparation and use
11/01/2001	WO2001081562A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
11/01/2001	WO2001081554A1 Pneumovirus ns proteins antagonising the interferon (ifn) response
11/01/2001	WO2001081413A2 Isolated human transporter proteins, nucleic acids and uses thereof
11/01/2001	WO2001081412A2 Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
11/01/2001	WO2001081409A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/01/2001	WO2001081408A2 G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
11/01/2001	WO2001081387A1 Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferation of cancer cell using the expression vector
11/01/2001	WO2001081360A1 Novel, photo-labile cumarinylmethyl esters of cyclic nucleotides, method for the production and use thereof
11/01/2001	WO2001081348A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
11/01/2001	WO2001081346A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta
11/01/2001	WO2001081343A2 Compounds for treating fibromyalgia and chronic fatigue syndrome
11/01/2001	WO2001081342A2 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
11/01/2001	WO2001081340A2 Heterocycles that are inhibitors of impdh enzyme
11/01/2001	WO2001081337A1 Inhibitors of dipeptidyl peptidase iv
11/01/2001	WO2001081334A2 Cyclic amidine compounds and their use as alpha4beta2 nicotinic acetylcholine receptor ligands
11/01/2001	WO2001081333A2 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
11/01/2001	WO2001081332A2 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
11/01/2001	WO2001081325A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
11/01/2001	WO2001081318A1 4-hydroxycinnoline-3-carboxyamides as antiviral agents
11/01/2001	WO2001081316A2 Substituted phenyl farnesyltransferase inhibitors
11/01/2001	WO2001081314A1 Naphthamidine urokinase inhibitors
11/01/2001	WO2001081312A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
11/01/2001	WO2001081311A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
11/01/2001	WO2001081310A1 1-aroyl-piperidinyl benzamidines
11/01/2001	WO2001081304A1 Inhibitors of dipeptidyl peptidase iv
11/01/2001	WO2001081303A1 Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
11/01/2001	WO2001081298A2 Cyclic carboxylic acids as integrin antagonists
11/01/2001	WO2001081295A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists
11/01/2001	WO2001080900A2 Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
11/01/2001	WO2001080893A1 Medicinal compositions promoting bowel movement
11/01/2001	WO2001080882A2 Methods and compositions for eliciting an immune response
11/01/2001	WO2001080876A1 Utilization of adamts-1 protein and method of screening aggrecanase activity regulator
11/01/2001	WO2001080875A1 A memory enhancing protein
11/01/2001	WO2001080860A2 Daily treatment for erectile dysfunction using a pde5 inhibitor
11/01/2001	WO2001080857A1 Zolpidem hemitartrate
11/01/2001	WO2001080847A2 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
11/01/2001	WO2001080845A2 (2-aminoethyl) oxime derivatives for the treatment of depression
11/01/2001	WO2001080844A2 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
11/01/2001	WO2001080832A2 Administration of a thiol-based chemoprotectant compound
11/01/2001	WO2001080823A2 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
11/01/2001	WO2001080811A2 Mmp-2 propeptide for use as antiangiogenic or antitumor agent
11/01/2001	WO2001080633A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/01/2001	WO2001056573A8 Use of cox-2 inhibitors as gastroprokinetics
11/01/2001	WO2001044239A3 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
11/01/2001	WO2001042231A3 Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
11/01/2001	WO2001041762A3 Valdecoxib compositions
11/01/2001	WO2001041761A3 Valdecoxib compositions
11/01/2001	WO2001038311A3 Pyrimidine derivatives as selective inhibitors of cox-2
11/01/2001	WO2001036641A3 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
11/01/2001	WO2001034640A3 Peptide (virip) which inhibits a circulating virus in humans and the use thereof
11/01/2001	WO2001032866A3 Hybrid adaptor receptors
11/01/2001	WO2001030736A3 Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors
11/01/2001	WO2001029049A3 Imidazole derivatives as phosphodiesterase vii inhibitors
11/01/2001	WO2001029025A3 Tyrosine kinase inhibitors
11/01/2001	WO2001029015A3 Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
11/01/2001	WO2001021620A3 Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines
11/01/2001	WO2001014318A3 New effectors of dipeptidyl peptidase iv for topical use
11/01/2001	WO2001010847A3 Novel integrin receptor antagonists
11/01/2001	WO2000066111A9 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
11/01/2001	WO2000056742A9 Organic-arsenic compounds
11/01/2001	WO2000043036A3 Lipoprotein complexes and compositions containing them
11/01/2001	US20010037026 Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst
11/01/2001	US20010037021 11-keto-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo(c,f)( 1,2)thiazepine is reacted with sodium borohydride in presence of chlorinated solvent and a catalyst to form alcohol, then chlorinating to form chloride, finally forming a salt
11/01/2001	US20010036960 Carvedilol-lipophilic solutions
11/01/2001	US20010036956 Estrogen receptor modulators
11/01/2001	US20010036953 Pyridyl-1,2,5-thiadiazole derivatives
11/01/2001	US20010036949 Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
11/01/2001	US20010036948 Administering a vascular alkylating compound; prevention restenosis
11/01/2001	US20010036946 Antiinflammatory agents
11/01/2001	US20010036944 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
11/01/2001	US20010036943 Mixture of analgesic and carrier
11/01/2001	US20010036942 Nervous system disorders
11/01/2001	US20010036936 Compositions and methods for treating osteoporosis
11/01/2001	US20010036930 Therapeutic azide compounds
11/01/2001	US20010036927 Complexing
11/01/2001	US20010036923 Complex
11/01/2001	US20010036919 Preventing airway mucus production by administration of EGF-R antagonists
11/01/2001	US20010036500 For enriching foods or beverages, anemia treatment
11/01/2001	US20010036479 Having preferred particle size distribution characteristics; antidiabetic agent
11/01/2001	US20010036470 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(ii) complexes
11/01/2001	US20010036462 Enhancing immunology response
11/01/2001	US20010036459 Cytotoxicity; therapeutic antibody
11/01/2001	US20010036456 Administering Protein C
11/01/2001	CA2407663A1 Inhibitors of dipeptidyl peptidase iv
11/01/2001	CA2407662A1 Inhibitors of dipeptidyl peptidase iv
11/01/2001	CA2407519A1 Daily treatment for erectile dysfunction using a pde5 inhibitor
11/01/2001	CA2407445A1 Use of 5-thio-, sulfinyl- and sulfonylpyrazolo¬3,4-b\|-pyridines as cyclin dependent kinase inhibitors
11/01/2001	CA2407370A1 Heterocycles that are inhibitors of impdh enzyme
11/01/2001	CA2407093A1 Substituted phenyl farnesyltransferase inhibitors
11/01/2001	CA2407084A1 Isolated human transporter proteins, nucleic acids and uses thereof
11/01/2001	CA2407081A1 Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
11/01/2001	CA2407077A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof

1 ... 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 ... 1564